Literature DB >> 226561

A syndrome of apparent mineralocorticoid excess associated with defects in the peripheral metabolism of cortisol.

S Ulick, L S Levine, P Gunczler, G Zanconato, L C Ramirez, W Rauh, A Rösler, H L Bradlow, M I New.   

Abstract

A syndrome is described whose features, suggestive of primary mineralcorticoid excess, included hypertension, hypokalemia, low PRA, and responsiveness to spironolactone. Aldosterone levels were subnormal but as yet there has been no evidence of overproduction of other mineralocorticoids by chemical analysis or by bioassay of plasma and urinary extracts. The steroidal abnormalities that were observed involved peripheral matabolism rather than secretion. One patient exhibited a transient delay in reduction of the 3-keto group in the A ring, and both patients exhibited a decrease in the metabolism of cortisol to biologically inactive cortisone. This was shown by the marked decrease in the excretion of urinary metabolites bearing an 11-keto group and a decrease in the oxidation of 11 alpha-[3H]cortisol to tritiated water. The defect appeared not to be a deficiency of the 11 beta-oxidoreductase system itself, since the reverse reaction of conversion of cortisone to cortisol proceeded normally, but, rater, an alteration in the equilibrium position of 11 beta-oxidoreduction in favor of the reduced form. This was also expressed by a prolongation of the half-time of disappearance of cortisol. The decrease in the MCR permitted the maintenance of normal cortisol plasma levels and normal glucocorticoid function at a diminished rate of secretion. The decreased rate of conversion of cortisol to cortisone serves as a biochemical marker of this hypertensive syndrome.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 226561     DOI: 10.1210/jcem-49-5-757

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  44 in total

Review 1.  Apparent mineralocorticoid excess syndromes.

Authors:  M Shimojo; P M Stewart
Journal:  J Endocrinol Invest       Date:  1995 Jul-Aug       Impact factor: 4.256

Review 2.  Primary aldosteronism.

Authors:  R D Gordon
Journal:  J Endocrinol Invest       Date:  1995 Jul-Aug       Impact factor: 4.256

Review 3.  Between candidate genes and whole genomes: time for alternative approaches in blood pressure genetics.

Authors:  Jacob Basson; Jeannette Simino; D C Rao
Journal:  Curr Hypertens Rep       Date:  2012-02       Impact factor: 5.369

4.  Evidence for cortisol as the mineralocorticoid in the syndrome of apparent mineralocorticoid excess.

Authors:  R Tedde; A Pala; A Melis; S Ulick
Journal:  J Endocrinol Invest       Date:  1992-06       Impact factor: 4.256

5.  Persistent hypokalemia after successful adrenalectomy in a patient with Cushing's syndrome due to ectopic ACTH secretion: possible role of 11beta-hydroxysteroid dehydrogenase inhibition.

Authors:  E Arteaga; C Fardella; C Campusano; I Cárdenas; P Martinez
Journal:  J Endocrinol Invest       Date:  1999-12       Impact factor: 4.256

Review 6.  11beta-HSD1, inflammation, metabolic disease and age-related cognitive (dys)function.

Authors:  Karen E Chapman; Jonathan R Seckl
Journal:  Neurochem Res       Date:  2007-10-25       Impact factor: 3.996

Review 7.  Aldosterone in the brain.

Authors:  Joel C Geerling; Arthur D Loewy
Journal:  Am J Physiol Renal Physiol       Date:  2009-03-04

Review 8.  Role of a disordered steroid metabolome in the elucidation of sterol and steroid biosynthesis.

Authors:  Cedric H L Shackleton
Journal:  Lipids       Date:  2011-08-27       Impact factor: 1.880

9.  Effect of biofeedback-assisted relaxation on blood pressure and cortisol levels in normotensives and hypertensives.

Authors:  A McGrady; M Woerner; G A Bernal; J T Higgins
Journal:  J Behav Med       Date:  1987-06

Review 10.  A genetic defect resulting in mild low-renin hypertension.

Authors:  R C Wilson; S Dave-Sharma; J Q Wei; V R Obeyesekere; K Li; P Ferrari; Z S Krozowski; C H Shackleton; L Bradlow; T Wiens; M I New
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-18       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.